QR-010 ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
299	Cystic fibrosis	2

299. Cystic fibrosis

---

Clinical trials : 1,696 /  Drugs : 1,644 - (DrugBank : 272) / Drug target genes : 96 - Drug target pathways : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02564354 (ClinicalTrials.gov)	September 2015	29/9/2015	Exploratory Study to Evaluate QR-010 in Subjects With Cystic Fibrosis ?F508 CFTR Mutation	Open-Label, Exploratory Study to Evaluate the Effects of QR-010 on Nasal Potential Difference in Subjects With CF With the ?F508 CFTR Mutation	Cystic Fibrosis	Drug: QR-010	ProQR Therapeutics	European Commission	Completed	18 Years	N/A	All	18	Phase 1	United States;Belgium;France
2	NCT02532764 (ClinicalTrials.gov)	June 2015	13/8/2015	Dose Escalation Study of QR-010 in Homozygous ?F508 Cystic Fibrosis Patients	Phase 1b, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of QR-010 in Subjects With Homozygous ?F508 Cystic Fibrosis	Cystic Fibrosis	Drug: QR-010;Drug: Placebo	ProQR Therapeutics	European Commission	Completed	18 Years	60 Years	All	70	Phase 1/Phase 2	United States;Belgium;Canada;Czechia;Denmark;France;Germany;Italy;Spain;United Kingdom;Czech Republic;Netherlands